1-[1-ethyl-6-(trifluoromethyl)benzimidazol-2-yl]-N-pyrimidin-5-ylsulfanylethanamine
C16H16F3N5S — CID 143667865
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[1-ethyl-6-(trifluoromethyl)benzimidazol-2-yl]-N-pyrimidin-5-ylsulfanylethanamine
1-[1-ethyl-6-(trifluoromethyl)benzimidazol-2-yl]-N-pyrimidin-5-ylsulfanylethanamine (PubChem CID 143667865) has the molecular formula C16H16F3N5S and a molecular weight of 367.40 g/mol. Its IUPAC name is 1-[1-ethyl-6-(trifluoromethyl)benzimidazol-2-yl]-N-pyrimidin-5-ylsulfanylethanamine.
Molecular Properties
| Compound Name | 1-[1-ethyl-6-(trifluoromethyl)benzimidazol-2-yl]-N-pyrimidin-5-ylsulfanylethanamine |
|---|---|
| PubChem CID | 143667865 |
| Molecular Formula | C16H16F3N5S |
| Molecular Weight | 367.40 g/mol |
| Exact Mass | 367.11 |
| IUPAC Name | 1-[1-ethyl-6-(trifluoromethyl)benzimidazol-2-yl]-N-pyrimidin-5-ylsulfanylethanamine |
| SMILES | CCn1c(C(C)NSc2cncnc2)nc2ccc(C(F)(F)F)cc21 |
| InChI | InChI=1S/C16H16F3N5S/c1-3-24-14-6-11(16(17,18)19)4-5-13(14)22-15(24)10(2)23-25-12-7-20-9-21-8-12/h4-10,23H,3H2,1-2H3 |
| InChIKey | OWKNRAOZZQCPNP-UHFFFAOYSA-N |
| XLogP | 4.22 |
| TPSA | 55.63 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 25 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 367.40 |
| LogP ≤ 5 | 4.22 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'sulphur_nitrogen_single_bond', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 143667865 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.